Replies to post #617696 on NorthWest Biotherapeutics Inc (NWBO)

[Extremist223]

How did dcvax in mgmt methylated compare to using optune's device?

Mgmt methylated approval regardless of tumor location

Anybody (LL even stated it) would assume that -L had the most benefit with near total resection while not being as effective with a larger remaining tumor as the immune system is good at killing a few cells but not as effective against a large mass. Yet, the trial results supposedly showed otherwise.

This point has been made before and while it is a decent point, she was drawing her conclusions from a small amount of patients. Is she not right that mgmt methylated has more mutations and therefore is more likely to work with dcvax?

She didn't get everything wrong, you just make it seem like that. As always.

Everyone knows that tumor mutation burden for GBM is pretty low compared to many other cancers. If the immune data comes out (hopefully soon) and it is unequivocal, I don't see why a blanket approval isn't the way to go for all mgmt methylated tumors with equal or greater mutation burden.

This biotech stock and its story is exactly the type of plot line needed to blow up market makers. Small company, with a massive chance at a blockbuster, without side effects.

I haven't seen a better idea for bankrupting market makers than revised endpoints + immune data and broadbased biomarker approval.

Ex has always been busy trashing her life's work and looking only for where she is wrong and not right. As if regulators will throw out data based on looking at only where she failed.

She doesn't have to predict the outcome to have merit. Even when I called National Security and was right it didn't matter.

It is okay to discover the truth.

[Dr Bala]

Didn't read beyond the first sentence of the fudster-extraordinaire's post. No need. Lack of understanding in the post of the FDA Oncology group's 2022 AOO article. Lack of understanding of the JAMA article. Lack of understanding of LL's talk. In fact, zero understanding of the trial results. The fudster-extraordinaire's posts are devoid of the least amount of understanding of the trial and the results.

[j e d]

curious if you think you’ve caught something here that the JAMA authors and reviewers did not. it’s possible none of them saw what you see—that, even though you’re not trained in this, you’re just inherently gifted—or that they saw it and ignored it, putting their reputations on the line?

how did this get past all the experts, but you picked up on it? actually curious what your thinking is on this.